首页 > 市场调查报告书 > 製药

再生医学细胞疗法

欧洲T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

市场调查报告书

商品编码

1452627

欧洲T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 78 Pages | 订单完成后即时交付

价格

简介目录图表

2022年欧洲T细胞治疗市值为6.9924亿美元，预计2030年将达到23.4549亿美元；预计2022年至2030年CAGR为16.3%。

T 细胞治疗批准数量的增加推动了欧洲 T 细胞治疗市场

标靶治疗、更快、更有效的恢復以及减少副作用都是 T 细胞疗法的优点。在全球范围内，由于获得了各种批准，细胞疗法被广泛采用。例如，

2023 年：欧盟委员会批准了 Breyanzi（lisocabtagene maraleucel；liso-cel），这是一种针对 CD19 的嵌合抗原受体 (CAR) T 细胞疗法。 CAR T 细胞疗法中发现的 4-1BB 共刺激结构域可增强 CAR T 细胞的扩增和持久性。第一线化疗难治的高级别B 细胞淋巴瘤(HGBCL)、瀰漫性大B 细胞淋巴瘤(DLBCL)、原发性纵隔大B 细胞淋巴瘤(PMBCL) 和3B 级滤泡性淋巴瘤(FL3B) 的成人或完成治疗后一年内復发的人有资格接受这种治疗。

2022 年：经欧洲人用医药产品委员会 (CHMP) 批准，Atara Biotherapeutics 的 Ebvallo 将成为世界上第一个获得许可的同种异体 T 细胞疗法。

2022年：吉利德公司旗下Kite宣布Yescarta（axicabtagene ciloleucel）已获得欧盟委员会批准用于治疗成人高级别B细胞淋巴瘤（HGBL）和瀰漫性大B细胞淋巴瘤（DLBCL）对一线化疗抗药性或完成化疗后一年内復发的人。

因此，越来越多的 T 细胞疗法获批正在推动市场成长。

欧洲T细胞治疗市场概况

欧洲 T 细胞治疗市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。德国和英国等国家预计将成为该地区市场的最大贡献者。血液系统恶性肿瘤和实体肿瘤盛行率的上升以及随后 T 细胞疗法批准的增加是推动欧洲市场成长的主要因素。

根据英国国家医疗服务体系 (NHS) 的数据，英国每年约有 800 人被诊断出患有急性淋巴性白血病，英国每年约有 5,500 人被诊断出患有 B 细胞淋巴瘤。由于英国白血病和淋巴瘤的流行，人们选择 T 细胞疗法来治疗这些癌症。由于 T 细胞疗法的知名度和积极成果，NHS 已与阿斯特捷利康等多家公司达成协议，以扩大个人化 CAR T 细胞疗法的使用范围。

欧洲 T 细胞治疗市场收入及 2030 年预测（百万美元）

欧洲T细胞治疗市场细分

欧洲 T 细胞治疗市场分为模式、治疗类型、适应症和国家。

根据模式，欧洲 T 细胞治疗市场分为研究和商业化。 2022年，商业化细分市场将占据更大的市场份额。

根据治疗类型，欧洲T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。 2022年，CAR T细胞疗法领域将占据更大的市场份额。

根据适应症，欧洲 T 细胞治疗市场分为血液恶性肿瘤和实体肿瘤。 2022 年，血液恶性肿瘤细分市场占据最大市场。

根据国家/地区，欧洲 T 细胞治疗市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。 2022 年，德国在欧洲 T 细胞治疗市场占据主导地位。

百时美施贵宝公司、吉利德科学公司、Immunocore Holdings Plc、信达生物製品公司、杨森全球服务有限责任公司、传奇生物科技公司和诺华公司是欧洲 T 细胞治疗市场上的一些领先公司。

In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.

In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.

In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Europe T Cell Therapy Market Overview

The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.

According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.

Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Europe T Cell Therapy Market Segmentation

The Europe T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Europe Market Analysis

5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe T Cell Therapy Market - Country Analysis

9.1 Europe

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Immunocore Holdings Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Legend Biotech Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Janssen Global Services LLC
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Gilead Sciences Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Novartis AG
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Europe T Cell Therapy Market Segmentation
Table 2. Europe T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. UK Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 26. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 27. Recent Organic Growth Strategies in Europe T Cell Therapy Market
Table 28. Recent Inorganic Growth Strategies in the Europe T Cell Therapy Market
Table 29. Glossary of Terms, Europe T Cell Therapy Market

List Of Figures

Figure 1. Europe T Cell Therapy Market Segmentation, By Country
Figure 2. Europe T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Growth Strategies in T Cell Therapy Market